292.35 6.90 (2.42%)
NSENov 26, 2020 03:31 PM
The 12 reports from 5 analysts offering long term price targets for Laurus Labs Ltd. have an average target of 398.33. The consensus estimate represents an upside of 36.25% from the last price of 292.35.
|Summary||Date||Stock||Broker||Price at Reco.||Target||Price at reco|
Change since reco(%)
|2020-11-01||Laurus Labs Ltd. +||Dolat Capital||291.35||400.00||291.35 (0.34%)||36.82||Accumulate|
Laurus reported robust 2Q beating our estimates primarily driven by stellar growth in formulations. Though majority growth is led by ARV tender based opportunities, leveraging its backward integration, Laurus has demonstrated commendable execution capability as the growth is volume led without any one-offs. Management remained confident of growth sustenance in 2H as well. In order to supplement future growth, Laurus has undertaken a massive capex program (Rs12bn) of which Rs5bn is allocated...
|2020-10-30||Laurus Labs Ltd. +||Sharekhan||300.85||385.00||300.85 (-2.83%)||31.69||Buy|
Synthesis and API segments are on track for a double digit growth. Operating leverage, favorable mix to support OPM expansion. Strong growth prospects, visibility on earnings, healthy balance sheet and return ratios are key positives We retain a Buy recommendation with a revised PT of Rs 385. Q2FY2021 was yet another stellar quarter for Laurus Labs Ltd (Laurus). Sales stood at Rs. 1138.8 crore, translating to a sturdy rise of 60% y-o-y on the back of robust growth in the lucrative formulations business and a double digit growth in the generic API's. Operating margins surprised positively, surging 1351 bps y-o-y to 32.8%, aided by an expansion...
|2020-10-30||Laurus Labs Ltd. +||BOB Capital Markets Ltd.||319.40||410.00||319.40 (-8.47%)||40.24||Buy|
|2020-09-29||Laurus Labs Ltd. +||ICICI Securities Limited||289.20||325.00||289.20 (1.09%)||Pre-Bonus/|
|2020-09-15||Laurus Labs Ltd. +||ICICI Securities Limited||1340.00||1620.00||1340.00 (-78.18%)||Pre-Bonus/|
|2020-08-19||Laurus Labs Ltd. +||BOB Capital Markets Ltd.||1063.15||1063.15 (-72.50%)||Pre-Bonus/|
|2020-08-01||Laurus Labs Ltd. +||Motilal Oswal||933.25||1215.00||933.25 (-68.67%)||Target met||Buy|
1 August 2020 Laurus Labs (LAURUS) delivered all-time high quarterly PAT at INR1.7b. It is more than average of annual PAT over FY17-20. The company expects this to be sustainable on the back of diversified portfolio, increased customer base, addition of capacity for API/formulation and supported with better operating leverage. After a long wait, the efforts towards product development/building manufacturing base are reflected in the phenomenal financial performance. In fact, 1QFY21 redefines the earnings assessment over near to medium term. Our target PE remains unchanged and target price of INR1,215 at 17x 12M forward earnings factors just the earnings upgrade. Sustainability of growth momentum in FY22 can drive further re-rating. Reiterate Buy. LAURUS 1QFY21 revenues grew at a robust rate of 77% YoY to INR9.7b INR3.5b v/s INR1.1b YoY, Other API (14% of sales) revenue of INR1.3b v/s INR440m YoY, 37% YoY growth in CDMO (10% of sales), and 19% YoY growth in Anti-Viral API (35% of sales).
|2020-07-31||Laurus Labs Ltd. +||BOB Capital Markets Ltd.||933.25||1200.00||933.25 (-68.67%)||Target met||Buy|
|2020-04-30||Laurus Labs Ltd. +||BOB Capital Markets Ltd.||512.50||630.00||512.50 (-42.96%)||Target met||Buy|
|2020-03-24||Laurus Labs Ltd. +||BOB Capital Markets Ltd.||341.90||510.00||341.90 (-14.49%)||Target met||Buy|
|2020-01-31||Laurus Labs Ltd. +||BOB Capital Markets Ltd.||430.35||510.00||430.35 (-32.07%)||Target met||Buy|
|2019-11-28||Laurus Labs Ltd. +||BOB Capital Markets Ltd.||350.25||480.00||350.25 (-16.53%)||Target met||Buy|
|2019-11-01||Laurus Labs Ltd. +||Motilal Oswal||378.30||440.00||378.30 (-22.72%)||Target met||Buy|
ARV-API (-23% YoY) and Hep-C (-47% YoY), however, were weak. Product mix superior: Gross margin expanded 295bp YoY to 49.5%, led by the increased share of FDF sales. EBITDA margin too improved 385bp YoY to 19.3% (our estimate: 17%), led by a better product mix and lower opex (75bp YoY). EBITDA increased 51% YoY to INR1.4b (our estimate: INR1.1b). PAT doubled YoY to INR566m, driven by strong sales growth, superior margins and a lower tax rate. For 1HFY20, revenue/EBITDA/PAT were up 12%/34%/118% YoY to INR12.6b/INR2.3b/INR716m. Key concall highlights: (1) LAURUS has garnered mid-teen market share in...
|2019-11-01||Laurus Labs Ltd. +||BOB Capital Markets Ltd.||378.30||480.00||378.30 (-22.72%)||Target met||Buy|
BOB Capital Markets Ltd.
Laurus Labs reported its best-ever EBITDA in Q2FY20 with a good topline beat, led by strong operating leverage in the formulation business and gross margin expansion.
|2019-08-05||Laurus Labs Ltd. +||HDFC Securities||319.95||470.00||319.95 (-8.63%)||Target met||Buy|
Laurus is sitting on ~40% underutilized gross block (~Rs 0.9bn) spread across formulations, CRAMS and API segments. With a sharp jump witnessed in formulations and higher visibility of CRAMS orders for FY20, we are confident that the operating/ financial leverage story will unfold from FY20. Assuming formulations revenues/ EBITDA at US$ 85/ 25mn in FY21E, earnings are likely to grow 2.5x over FY19-21E. With all four ARV formulation approvals (TLD, TLE 400, TLE 600, TEE) in place by 1HFY21, addressing >US$ 1.2bn opportunity, the estimates could be breached easily. Maintain BUY. We maintain a BUY on Laurus despite poor operational performance in 1QFY20. After adjusting for lack of scale up in ARV APIs and buoyancy in formulation segment, we have cut our FY20/21E numbers by 5-8% to arrive at a TP of Rs 470/sh (18x FY21E EPS).
|2019-08-05||Laurus Labs Ltd. +||BOB Capital Markets Ltd.||319.95||480.00||319.95 (-8.63%)||Target met||Buy|
|2019-05-06||Laurus Labs Ltd. +||HDFC Securities||389.35||535.00||389.35 (-24.91%)||Target met||Buy|
With buoyant 4QFY19 numbers, we remain constructive on Laurus and believe it is best-positioned to successfully transition into a formulations and CRAMS player. This will lead to improved profitability in the coming years, driven by better business mix and operating/financial leverage. Laurus entered the US$ 1.8bn ARV formulations market in FY19. In our view, it can capture at least 15% market share (in TLE/TEE/TLD), supported by one of the largest ARV API capacities. With formulations revenues/EBITDA at US$ 85/25mn in FY21E, earnings can triple over FY19-21E (on a soft base). We also expect a couple of big-ticket formulations launches in the US market by FY21, which can further boost profitability. We strongly believe the stock is ripe for healthy returns. We maintain a BUY on Laurus following a bumper (yet inline) 4QFY19. Our TP is unchanged at Rs 535/sh (18x FY21E EPS). The delivery has begun.
|2019-05-03||Laurus Labs Ltd. +||Motilal Oswal||397.20||470.00||397.20 (-26.40%)||Target met||Buy|
3 May 2019 increased 13.4% YoY to INR6.3b (v/s our est. of INR5.6b), led by (i) strong growth in Onco APIs (11% of sales; +91% YoY), (ii) other APIs (10% of sales; +40% YoY), and (iii) Synthesis (15% of sales; +74% YoY). Formulation sales came in at INR282m v/s INR14m in 4QFY18. Hep-C API sales increased to INR415m from INR197m in 3QFY19. However, growth was impacted by a reduction in base ARV-API business (50% of sales; -14% YoY). (GM) shrank 190bp YoY to 46% due to a change in the product mix. EBITDA margin contracted 320bp YoY to 17.6% owing to lower GM and higher other expenses (16.9% v/s 15.2% in 4QFY18). On QoQ basis, there has been 100bp/330bp improvement in GM/EBITDA margin. Adjusting for transfer of ANDA rights to Casi pharma in 3QFY19, PAT was down 4% YoY to INR432m (v/s our est.
|2019-04-10||Laurus Labs Ltd. +||Motilal Oswal||404.00||470.00||404.00 (-27.64%)||Pre-Bonus/|
10 April 2019 Laurus is looking to ramp up the commercial production of its anti-retroviral (ARV) products after (a) developing products, (b) spending considerable capex (~INR4.2b) to build its formulation facility, and (c) filing products with institutional and regulatory agencies (for the LMIC-WHO/US/EU market) for its ARV products. Post the receipt of approval from the USFDA, Laurus has received an order from Global Fund to supply Tenofovir-Lamivudine-Dolutegravir (TLD) as part of a 3.5-year agreement. Further, Laurus is continuing to develop its product pipeline for the US market. Laurus has completed the expansion for Lamivudine with its offtake expected to increase over the near term. Hence, we expect the ARV API business to grow moderately to INR17b by FY21E, continuing to remain Laurus backbone by contributing 65% to total sales. We expect Laurus Synthesis business to remain strong growing at 33% CAGR with revenues of INR3.
|2019-03-28||Laurus Labs Ltd. +||HDFC Securities||404.45||535.00||404.45 (-27.72%)||Pre-Bonus/|
We maintain BUY with a TP of Rs 535 (18x FY21E EPS). Laurus has received Global Fund orders for the HIV drug, TLD, following a tentative approval from the US FDA last month. This is a big positive for the company and reinstates investor confidence in the business, with the formulations segment finally beginning to fire. With volume commitment for TLD from the Global Fund for the next 3.5 years, as well as ~US$ 12-15mn orders in hand from an EU partner and ongoing supplies of Metformin and HCQ to the US, we have high visibility on ~US$ 40mn formulations revenue in FY20E.